Your (e.g., comfortable with high volatility)? Your investment timeframe ?
Strategy: Market-cap weighted, dominated by giants like Vertex, Gilead, and Amgen . Expense Ratio: 0.44% . Best for: Low-cost core exposure . best biotech etf to buy now
Strategy: Actively managed by Cathie Wood's team, targeting "disruptive" innovation . Expense Ratio: 0.75% . Comparison of Key Metrics 1-Year Return Expense Ratio Small/Mid-Cap Equal Weight IBB Large-Cap Market Weighted SBIO Clinical Trial Breakthroughs IBBQ Nasdaq Biotech Index Data based on recent 2026 market reports . Your (e
Strategy: Tracks the Nasdaq Biotechnology Index at a significantly lower price point . Expense Ratio: 0.19% . Expense Ratio: 0
Best for: Speculative bets on high-frontier tech like gene editing and CRISPR .
AI responses may include mistakes. For financial advice, consult a professional. Learn more